Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

NUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

NUEDEXTA Important Safety Information

NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindica
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... STUDY OBJECTIVES The objective of ... an overview of the current and future characteristics ... key objective is to present a comprehensive analysis ... important tool in the treatment of various diseases. ... within the protein therapeutics market, which includes peptide ...
(Date:9/30/2014)...  Decision Resources Group finds that the Asia Pacific ... China , India , ... through 2023. Dental implant procedure volumes will grow as physicians are ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... LOS ANGELES , Sept. 30, 2014   ... apnea shopping destination , today announced that it now ... ResMed . AirSense CPAPs are the first sleep apnea ... makes it simple and easy to track and share ... the overall effectiveness of their CPAP therapy.  In addition, ...
Breaking Medicine Technology:Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 2Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 3Global Markets and Manufacturing Technologies for Protein Drugs -- Focus on Cytokines and Monoclonal Antibodies 4Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... WOONSOCKET, R.I., Jan. 6, 2011 A new CVS ... a three-year period for patients with one or more ... medications as doctors direct may save the health care ... study findings revealed robust reductions in emergency department visits ...
... DIEGO, Jan. 6, 2011 Arena Pharmaceuticals, Inc. (Nasdaq: ... is scheduled to present at the 29th Annual J.P. Morgan ... Pacific Time (7:00 p.m. Eastern Time) at the Westin St. ... and Chief Executive Officer, is scheduled to provide a corporate ...
Cached Medicine Technology:CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending 2CVS Caremark Study Finds Medication Adherence Leads to Lower Health Care Costs, Even After Accounting for Increased Prescription Drug Spending 3Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Arena Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference 3
(Date:10/1/2014)... (PRWEB) October 01, 2014 ... networking and relationship-marketing firm, announced today the ... Executive® and Project of the Year Awards ... makers representing organizations in financial services, commercial, ... large-scale technology endeavors that address key issues ...
(Date:10/1/2014)... October 01, 2014 Beverly Hills licensed ... Mojas is celebrating 20 years of private practice in ... of people to achieve greater joy and fulfillment in ... of warning signs and suggestions for anyone who suspects ... explains: “Believe it or not, it’s not always ...
(Date:10/1/2014)... 01, 2014 NoteSwift Inc., announced today ... 10.0, 12.1 and 13.0. NoteSwift is the bridge between ... to navigate and document clinical information at the point ... creating a patient note by more than half – ... major pain points providers state impedes EHR use according ...
(Date:10/1/2014)... in Bahir Dar, Ethiopia, at the occasion of ... gathered some 150 African and international leishmaniasis experts, ... safety and efficacy monitoring plan, carried out ... Sudan, Uganda, and Ethiopia, were presented to key ... to treatment of kala-azar with the combination of ...
(Date:10/1/2014)... Dr. Saj Jivraj, one of the ... traveling to Chennai, India, tomorrow to speak at the ... 3. , Dr. Jivraj is founder of the Anacapa ... and one of the world’s foremost prosthodontists, meaning he ... is speaking to the Indian Society of Oral Implantologists ...
Breaking Medicine News(10 mins):Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:Results of large-scale roll out of combination treatment for kala-azar in Eastern Africa 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 2Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 3Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 4Health News:One of Woodland Hills’ Top Cosmetic Dentists Speaking to Indian Society of Oral Implantologists Tomorrow 5
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... they have found a correlation between asthma and lung cancer ... a correlation between chronic obstructive pulmonary disease (COPD) and lung ... has been shown for asthma and lung cancer, the researchers ...
... the association for informatics professionals, has been selected to ... National Priorities Partnership (NPP), beginning Sept. 21, 2010. ... Quality Forum (NQF) will reconstitute the NPP, which currently ... U.S. health care system. The NPP,s previous work has ...
... Nov. 3, 2010 The U.S. Department of Veterans Affairs ... the highest honor it bestows on scientists. Lee, ... of Orthopaedic Surgery, will receive $1.4 million to support his ... VA Medical Center. "Dr. Lee is one of the ...
... the demand for organically produced food increasing, scientists are ... potatoes generally do not have higher levels of healthful ... fertilizers and pesticides. Their study appears in ACS, bi-weekly ... In the study, Pia Knuthsen and colleagues point out ...
... HealthDay Reporter , TUESDAY, Nov. 2 (HealthDay News) -- The ... job of properly monitoring the safety of medical devices, the ... the authority to approve both drugs and medical devices, but ... and safety is lax in both its initial approval of ...
... and Research Center at the University of California, San ... compounds may be effective in treating both alcohol and ... a paper published in the November 3, 2010 issue ... consumption in rodents was significantly decreased by two compounds ...
Cached Medicine News:Health News: Asthma Linked to Lung Cancer Risk in Study 2Health News:National Quality Forum picks AMIA for national priorities partnership 2Health News:VA names UCI orthopedic biomedical engineer a senior research career scientist 2Health News: FDA Failing to Monitor Safety of Medical Devices: Report 2Health News: FDA Failing to Monitor Safety of Medical Devices: Report 3Health News: FDA Failing to Monitor Safety of Medical Devices: Report 4Health News:New compounds may treat both alcohol and cigarette addictions 2
... Made with elastic fabric, these head ... you need to begin testing. Each Electro-Cap ... to the International 10-20 System. When you ... you are using with your head cap ...
... When testing takes you into the OR, ER, ... protection of Cadwells new shielded electrodes. Keeping noise ... and paired disc electrode has a special shielded ... the damaging effects of 60-cycle interference. That means ...
... orbital implant was conceived by Arthur C. ... a comprehensive review of the literature on ... dating back to 1885 (Mules 1885). This ... the performance of contemporary implants, allowed Perry ...
... Viewing System was developed in New ... the surgical supervision of Professor Stanley Chang, ... New York Cornell Medical Center and later ... on the market and immediately revolutionized the ...
Medicine Products: